Adipose tissue dysfunction in nascent metabolic syndrome.

Area of Science:

• Endocrinology
• Metabolic Diseases
• Immunology

Background:

• Metabolic syndrome (MetS) increases risks for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).
• Limited research exists on adipose tissue in early MetS stages before T2DM or CVD development.
• Adipose tissue dysregulation and aberrant adipokine secretion are implicated in MetS's chronic inflammation and insulin resistance.

Purpose of the Study:

• To investigate adipose tissue biology in subjects with nascent MetS.
• To identify specific adipokine profiles associated with early-stage MetS.
• To understand the role of subcutaneous adipose tissue (SAT) dysfunction in MetS pathogenesis.

Main Methods:

• Analysis of subcutaneous adipose tissue (SAT) and plasma from subjects with nascent MetS.
• Assessment of macrophage recruitment and crown-like structures in SAT.
• Quantification of various SAT-secreted and plasma adipokines, including IL-1, IL-6, leptin, RBP-4, CRP, SAA, PAI-1, MCP-1, chemerin, adiponectin, and omentin-1.

Main Results:

• Subjects with nascent MetS exhibited increased macrophage recruitment and crown-like structures in SAT.
• Elevated levels of SAT-secreted and plasma adipokines (e.g., IL-1, IL-6, leptin, CRP) were observed.
• Decreased levels of plasma adiponectin and omentin-1 (both plasma and SAT) were found, persisting even after adjusting for adiposity.

Conclusions:

• Subcutaneous adipose tissue dysfunction is crucial in MetS, characterized by inflammation and altered adipokine profiles.
• The observed adipokine profile contributes to low-grade inflammation and insulin resistance.
• These findings highlight SAT dysfunction's role in the increased risk of T2DM and CVD associated with MetS.